Cornerstone Sues Exela Over Generic Hypertension Drug

Law360, New York (July 24, 2013, 4:41 PM ET) -- Cornerstone Therapeutics Inc. on Wednesday told a Delaware federal judge that Exela Pharma Sciences LLC infringed two of its patents when it asked the FDA to approve a generic version of its hypertension drug before the original patent expired.

Cornerstone's complaint asked the court for preliminary and permanent injunctions to stop Exela from developing and selling a generic version of Cornerstone’s drug, Cardene I.V. Premixed Injection, an intravenous, short-term treatment for hypertension that it markets as an alternative to oral therapy.

Exela sent Cornerstone a letter...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required